Literature DB >> 895003

[Critical analysis of the saralasintest in the diagnosis of hypertension (author's transl)].

A Röckel, H Wernze, B Sabel, A Heidland.   

Abstract

The reliability of the angiotensin II (AT II)-antagonist Saralasin in the diagnosis of AT II-dependent forms of hypertension was investigated in 61 cases of hypertension of different etiology. In 14 patients, lowering of blood pressure by Saralasin suggested an AT II-dependent hypertension which could be ascertained in 8 patients (5 had undergone successful surgery) by increased levels of plasma-renin-activity (PRA), AT II, PRA-ratio in renal vein blood and by angiography. Besides, depressor reactions by Saralasin yielded additional information in three patients with renovascular hypertension but normal levels of PRA and AT II, in two patients with high renin essential hypertension and one patient with pheochromocytoma. This test seems to be valuable in the diagnosis of renin-dependent hypertension.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 895003     DOI: 10.1007/bf01482536

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  32 in total

1.  Radioimmunoassay and pharmacokinetics of saralasin in the rat and hypertensive patients.

Authors:  W A Pettinger; K Keeton; K Tanaka
Journal:  Clin Pharmacol Ther       Date:  1975-02       Impact factor: 6.875

2.  THE ACTION OF PEPTIDES ON THE ADRENAL MEDULLA. RELEASE OF ADRENALINE BY BRADYKININ AND ANGIOTENSIN.

Authors:  W FELDBERG; G P LEWIS
Journal:  J Physiol       Date:  1964-05       Impact factor: 5.182

3.  [Diagnostic relevancy of saralasin in renin-dependent hypertension].

Authors:  A Röckel; H Wernze; H J Spech; E Scheitza; H Hennemann; A Heidland
Journal:  Verh Dtsch Ges Inn Med       Date:  1976

4.  [The renin-angiotensin system: metodical and clinical problems. Report of a workshop held November 23/24 in Würzburg].

Authors:  H Wernze; J Rosenthal
Journal:  Med Welt       Date:  1976-01-30

5.  Identification of angiotensinogenic hypertension in man using 1-sar-8-ala-angiotensin II (Saralasin, P-113).

Authors:  D H Streeten; J M Freiberg; G H Anderson; T G Dalakos
Journal:  Circ Res       Date:  1975-06       Impact factor: 17.367

6.  Inhibition of renin secretion by systemic and intrarenal angiotensin infusion.

Authors:  J R Blair-West; J P Coghlan; D A Denton; J W Funder; B A Scoggins; R D Wright
Journal:  Am J Physiol       Date:  1971-05

7.  Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure.

Authors:  H R Brunner; H Gavras; J H Laragh
Journal:  Lancet       Date:  1973-11-10       Impact factor: 79.321

8.  Plasma renin activity in pheochromocytoma.

Authors:  M Maebashi; Y Miura; K Yoshinaga; K Sato
Journal:  Jpn Circ J       Date:  1968-10

9.  Hypertension associated with vascular lesion of neurofibromatosis.

Authors:  A B Burns; H Tesluk; J M Palmer
Journal:  J Urol       Date:  1972-11       Impact factor: 7.450

10.  Saralasin bolus test. Rapid screening procedure for renin-mediated hypertension.

Authors:  L S Marks; M H Maxwell; J J Kaufman
Journal:  Lancet       Date:  1975-10-25       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.